suramin has been researched along with Experimental Mammary Neoplasms in 5 studies
Suramin: A polyanionic compound with an unknown mechanism of action. It is used parenterally in the treatment of African trypanosomiasis and it has been used clinically with diethylcarbamazine to kill the adult Onchocerca. (From AMA Drug Evaluations Annual, 1992, p1643) It has also been shown to have potent antineoplastic properties.
suramin : A member of the class of phenylureas that is urea in which each of the amino groups has been substituted by a 3-({2-methyl-5-[(4,6,8-trisulfo-1-naphthyl)carbamoyl]phenyl}carbamoyl)phenyl group. An activator of both the rabbit skeletal muscle RyR1 and sheep cardiac RyR2 isoform ryanodine receptor channels, it has been used for the treatment of human African trypanosomiasis for over 100 years.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Treatment with suramin also decreased the levels of FGF receptor-1 mRNA to a similar extent, whereas it appeared not to affect the levels of beta-actin mRNA." | 1.29 | Suramin interrupts androgen-inducible autocrine loop involving heparin binding growth factor in mouse mammary cancer (Shionogi carcinoma 115) cells. ( Kasayama, S; Kouhara, H; Saito, H; Sato, B; Sumitani, S, 1993) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (20.00) | 18.7374 |
| 1990's | 4 (80.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kasayama, S | 1 |
| Saito, H | 1 |
| Kouhara, H | 1 |
| Sumitani, S | 1 |
| Sato, B | 1 |
| Enomoto, K | 1 |
| Furuya, K | 1 |
| Yamagishi, S | 1 |
| Oka, T | 1 |
| Maeno, T | 1 |
| Rahimi, N | 1 |
| Tremblay, E | 1 |
| McAdam, L | 1 |
| Park, M | 1 |
| Schwall, R | 1 |
| Elliott, B | 1 |
| Zhu, G | 1 |
| Oto, E | 1 |
| Vaage, J | 1 |
| Quinn, Y | 1 |
| Newman, M | 1 |
| Engbers, C | 1 |
| Uster, P | 1 |
| Balzarini, J | 1 |
| Mitsuya, H | 1 |
| De Clercq, E | 1 |
| Broder, S | 1 |
5 other studies available for suramin and Experimental Mammary Neoplasms
| Article | Year |
|---|---|
Suramin interrupts androgen-inducible autocrine loop involving heparin binding growth factor in mouse mammary cancer (Shionogi carcinoma 115) cells.
Topics: Animals; Cattle; Cell Division; Fibroblast Growth Factor 1; Fibroblast Growth Factor 2; Humans; Mamm | 1993 |
The increase in the intracellular Ca2+ concentration induced by mechanical stimulation is propagated via release of pyrophosphorylated nucleotides in mammary epithelial cells.
Topics: Adenosine Triphosphate; Animals; Calcium; Epithelial Cells; Epithelium; Female; Fura-2; Mammary Neop | 1994 |
Identification of a hepatocyte growth factor autocrine loop in a murine mammary carcinoma.
Topics: 3T3 Cells; Adipocytes; Animals; Antineoplastic Agents; Dogs; Female; Hepatocyte Growth Factor; Kidne | 1996 |
The effect of vincristine-polyanion complexes in STEALTH liposomes on pharmacokinetics, toxicity and anti tumor activity.
Topics: Animals; Anions; Anticoagulants; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Dextran S | 1996 |
Aurintricarboxylic acid and Evans Blue represent two different classes of anionic compounds which selectively inhibit the cytopathogenicity of human T-cell lymphotropic virus type III/lymphadenopathy-associated virus.
Topics: Animals; Aurintricarboxylic Acid; Azo Compounds; Benzhydryl Compounds; Cell Division; Cyclohexanecar | 1986 |